Acuta Capital Partners LLC Takes $1.29 Million Position in NewAmsterdam Pharma (NASDAQ:NAMS)

Acuta Capital Partners LLC purchased a new stake in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 50,000 shares of the company's stock, valued at approximately $1,285,000. NewAmsterdam Pharma accounts for approximately 1.3% of Acuta Capital Partners LLC's holdings, making the stock its 25th largest position. Acuta Capital Partners LLC owned 0.05% of NewAmsterdam Pharma as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. National Bank of Canada FI acquired a new position in NewAmsterdam Pharma in the fourth quarter valued at about $51,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in NewAmsterdam Pharma during the 4th quarter worth about $80,000. KLP Kapitalforvaltning AS purchased a new position in shares of NewAmsterdam Pharma in the fourth quarter valued at approximately $154,000. Barclays PLC grew its holdings in shares of NewAmsterdam Pharma by 1,813.4% in the third quarter. Barclays PLC now owns 7,596 shares of the company's stock valued at $126,000 after purchasing an additional 7,199 shares in the last quarter. Finally, The Manufacturers Life Insurance Company purchased a new position in NewAmsterdam Pharma in the 4th quarter valued at approximately $221,000. Institutional investors and hedge funds own 89.89% of the company's stock.

Insider Buying and Selling at NewAmsterdam Pharma

In other news, CAO Louise Frederika Kooij sold 150,000 shares of the firm's stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $20.37, for a total transaction of $3,055,500.00. Following the sale, the chief accounting officer now owns 15,000 shares in the company, valued at $305,550. This trade represents a 90.91 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director James N. Topper bought 1,135 shares of NewAmsterdam Pharma stock in a transaction that occurred on Wednesday, March 26th. The shares were acquired at an average price of $22.49 per share, for a total transaction of $25,526.15. Following the completion of the transaction, the director now directly owns 3,013,569 shares of the company's stock, valued at $67,775,166.81. This trade represents a 0.04 % increase in their position. The disclosure for this purchase can be found here. 19.50% of the stock is currently owned by insiders.

NewAmsterdam Pharma Stock Up 0.1 %

NAMS stock traded up $0.02 on Wednesday, reaching $19.02. 310,308 shares of the company's stock were exchanged, compared to its average volume of 606,900. NewAmsterdam Pharma has a twelve month low of $14.06 and a twelve month high of $27.29. The firm has a market cap of $2.09 billion, a PE ratio of -7.30 and a beta of 0.01. The stock has a fifty day moving average of $19.65 and a 200-day moving average of $21.24.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.47). The company had revenue of $12.77 million during the quarter, compared to analysts' expectations of $3.30 million. On average, equities research analysts predict that NewAmsterdam Pharma will post -1.75 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

NAMS has been the subject of several analyst reports. Scotiabank boosted their target price on NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a "sector outperform" rating in a research note on Thursday, February 27th. UBS Group set a $41.00 price target on NewAmsterdam Pharma in a research note on Monday, March 3rd. HC Wainwright restated a "buy" rating and set a $48.00 target price on shares of NewAmsterdam Pharma in a research note on Tuesday, January 14th. Needham & Company LLC restated a "buy" rating and issued a $42.00 target price on shares of NewAmsterdam Pharma in a report on Tuesday, April 8th. Finally, Royal Bank of Canada reiterated an "outperform" rating and set a $40.00 price target on shares of NewAmsterdam Pharma in a research note on Friday, January 24th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $43.33.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.